New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
08:51 EDTIMUCImmunoCellular upgraded at Roth Capital
As previously reported, Roth Capital upgraded ImmunoCellular to Buy from Neutral. The firm upgraded shares following the update to the the Phase II ICT-107 study in front-line glioblastoma. The analyst believes a true addressable patient population has been identified and is optimistic on the next regulatory steps. Price target raised to $3 from $2.
News For IMUC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 19, 2015
16:31 EDTIMUCImmunoCellular enters ammended license agreement with Cedars-Sinai
Subscribe for More Information
May 11, 2015
16:09 EDTIMUCImmunoCellular reports Q1 EPS (2c), consensus (3c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use